ClinicalTrials.gg
CompletedNCT04884399Updated Mar 28, 2024

Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD

A Phase 1 interventional study of CMAB818 and Lucentis® in Wet Age-related Macular Degeneration, sponsored by Shanghai Biomabs Pharmaceutical Co., Ltd.. Completed at 4 sites in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by Shanghai Biomabs Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
97th of 124
24 · median 64
Started
2021
with 3 others
Phase 1
6 of 125
none open now
Registered
117th of 125
by date

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 97th largest by enrollment of the 124 interventional ones that give a count, is one of 4 that started in 2021, is one of 6 in phase 1, and was the 117th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

This is a randomized, double-blind, two-group parallel, positive-controlled clinical Phase I trial comparing the safety, pharmacokinetics, pharmacodynamics and efficacy of CMAB818 and Lucentis® in patients with wet age-related macular degeneration.

Read the detailed description

This is a phase I, randomized, double-blind, two-group parallel, positive-controlled clinical trial at four sites. Subjects will be sequentially enrolled according to the protocol in one of two cohorts and receive a single 0.5mg of CMAB818 or Lucentis® through intravitreal injection.

The primary objective is to assess the initial clinical safety of intravitreal injection of CMAB818 or Lucentis® in patients with wet age-related macular degeneration (wet-AMD).

The secondary objective are to assess immnogenicity, pharmacokinetic, pharmacodynamics and the initial clinical efficacy of intravitreal injection of CMAB818 or Lucentis® in patients with wet age-related macular degeneration (wet-AMD).

03

Conditions studied

  • Wet Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the , and able to receive follow-up according to the time stipulated by the trial;
  2. 50 years≤age≤80 years, male or female;
  3. The target eye must meet the following requirements: newly occurring or subfoveal and perifoveal active choroidal neovascularization (CNV) lesions secondary to AMD; the best corrected visual acuity between 78-19 letters (including the boundary value, using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts, equivalent to Snellen visual acuity of 20/32 to 20/400); no refractive media opacity or myosis affecting fundus examination;
  4. The best corrected visual acuity of the subject's non-target eye≥19 letters (using ETDRS charts, equivalent to Snellen visual acuity of 20/400).

Exclusion criteria

Exclusion Criteria:

  1. Previously received anti-VEGF drug treatment in either eye within 3 months before screening (e.g., aflibercept\<Eylea®>, ranibizumab\<Lucentis®>, bevacizumab\<Avastin®>, Conbercept\<Lumitin®>, etc.);
  2. Active eye infection in either eye within 1 months before screening (including but not limited to Blepharitis, Conjunctivitis infective, Keratitis, Scleritis, Endophthalmitis);
  3. History of vitreous hemorrhage within 3 months before screening;
  4. History or presence of uncontrolled glaucoma (defined as intraocular pressure(IOP)>25 mmHg despite treatment with maximal medical therapy),or the optic fovea/optical disc ratio of the target eye caused by severe glaucoma > 0.8;
  5. Previously received subconjunctival/intravitreal injection within 3 months (including subconjunctival/intravitreal long-acting implants within 6 months), or local ocular corticosteroids treatment in the target eye within 1 month before screening;
  6. Previously received the following ophthalmic surgery such as verteporfin photodynamic therapy (PDT), macular translocation, glaucoma filtering, subfoveal laser photocoagulation, vitrectomy and transpupillary thermotherapy, and other submacular surgery or surgery used to treat age-related macular degeneration in the target eye;
  7. Other ocular diseases other than wAMD that affect the central vision, such as dry AMD, venous occlusion, uveitis, diabetic retinopathy, vascular-like streaks, pathological myopia, retinal detachment, macular hole, etc. in the target eye;
  8. Aphakia (excluding intraocular lenses) or rupture of the posterior lens capsule in the target eye [except for yttrium aluminum garnet (YAG) laser posterior capsulotomy after intraocular lens implantation];
  9. History of rhegmatogenous retinal detachment or macular hole retinal detachment (stage 3 or 4), with retinal detachment, retinal pigment epithelial tear, or retinal traction in the macular area and epiretinal disease in the macular area in the target eye;
  10. Current use or may need to use systemic drugs that can cause crystal toxicity, such as psoralen, risedronate sodium, tamoxifen, etc.;
  11. Allergy to fluorescein sodium or indocyanine green, protein products for treatment or diagnosis, and more than 2 drugs and/or non-drugs;
  12. History of surgical operations (except for minimally invasive surgery that has healed) or currently unhealed wounds, moderate to severe ulcers, fractures, etc. within 1 month before screening;
  13. Presence of infectious diseases that require oral, intramuscular or intravenous administration;
  14. Presence of active diffuse intravascular coagulation or obvious bleeding tendency or abnormal coagulation function before screening ( ≥ 3 seconds of value, activated partial thromboplastin time ≥ 10 seconds of upper limit of normal value);
  15. History of myocardial infarction, cerebral infarction, unstable angina, coronary revascularization, New York College of Cardiology () grade ≥ grade II cardiac insufficiency, severely unstable ventricular arrhythmia, and cerebrovascular accident (including ) before screening;
  16. Presence of systemic immune diseases (including but not limited to systemic lupus erythematosus, immune hemolytic anemia, hyperthyroidism);
  17. Uncontrolled hypertension(defined assystolic blood pressure≥160 mmHg and/or diastolic blood pressure≥100 mmHg diastolic despite treatment with antihypertensive drugs;
  18. Diabetes with uncontrolled blood glucose (defined as fasting blood glucose≥7.0 mmol/L);
  19. Any uncontrollable clinical problems (including but not limited to serious mental, neurological, respiratory and other system diseases, as well as malignant tumors);
  20. (ALT) and/or aspartate aminotransferase (AST) higher than 1.5 times the laboratory upper limit of normal (ULN) and/or blood creatinine is higher than ULN and the investigator judges that the abnormality has clinical significance;
  21. Concurrent with (positive hepatitis B virus surface antigen), (positive hepatitis C virus antibody), AIDS (positive antibody) or syphilis (positive syphilis antibody);
  22. Pregnant and lactating women;
  23. Refuse to take effective measures during childbearing age throughout the study period;
  24. Participated in any drug (excluding vitamins and minerals) and medical device clinical trials within 3 months before screening (if the drug has a long half-life and its 5 half-life time is greater than 3 months, then choose the 5 half-life time);
  25. Any other situations that investigator thinks the subject is inappropriate to participate in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    CMAB818

    0.5 mg by intravitreal injection once on the first day.

    Drug: CMAB818

  • Active comparator
    Lucentis®

    0.5 mg by intravitreal injection once on the first day.

    Drug: Lucentis®

Interventions

  • vascular endothelial growth factor (VEGF) inhibitor

    Also known as: Ranibizumab Injection

  • vascular endothelial growth factor (VEGF) inhibitor

    Also known as: Ranibizumab Injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events That Are Related to Treatment

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant graded according to the common terminology criteria for adverse events (CTCAE) v.5.0 criteria, including clinically-significant changes in physical examinations, laboratory safety tests, ECG and vital signs

    Time frame: 0~42 days

Secondary outcomes

  1. Number of Participants With anti-drug antibody

    Blood samples were collected at the following time point: pre-dose, D14, D28, and D42

    Time frame: 0~42 days

  2. Percentage of neutralizing antibody

    Subjects with a positive antibody response to ranibizumab were determined to test neutralizing antibody

    Time frame: 0~42 days

  3. AUC(0-t)

    Blood samples were collected to measure the area under the concentration time curve from time 0 to last time

    Time frame: 0~42 days

  4. Cmax

    Blood samples were collected to measure maximum concentration

    Time frame: 0~42 days

  5. CL

    Blood samples were collected to measure clearance rate

    Time frame: 0~42 days

  6. Half-life (t1/2)

    Blood samples were collected to measure half-life time

    Time frame: 0~42 days

  7. Pharmacodynamics

    The plasma VEGF concentration from baseline were measured

    Time frame: 0~42 days

  8. Mean change in best corrected visual acuity (BCVA) from baseline

    BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visualacuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient

    Time frame: 0~42 days

  9. Mean change in central retinal thickness from baseline

    Central retinal thickness was measured using the Optical Coherence Tomography

    Time frame: 0~42 days

  10. Mean change in lesion area from baseline

    The lesion area was measured using Fundus Fluorescein Angiography

    Time frame: 0~42 days

  11. Mean change in leakage area from baseline

    The leakage area was measured using Fundus Fluorescein Angiography

    Time frame: 0~42 days

07

Study locations

4 sites
  • Peking University People'S Hospital
    Beijing, Beijing 100044, China
  • Beijing Tongren Hospital
    Beijing, Beijing 100730, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • Shanghai General Hospital
    Shanghai, Shanghai 200080, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Dec 2022, 18 months.

Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 18 months is above that.

Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2021
First posted
May 13, 2021
StartActual
Jun 3, 2021
Primary completionActual
Dec 22, 2022
CompletionActual
Dec 22, 2022
Last update
Mar 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04884399
Lead sponsor
Shanghai Biomabs Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
May 13, 2021
Start date
Jun 3, 2021
Primary completion
Dec 22, 2022
Completion
Dec 22, 2022
Last update
Mar 28, 2024

Study contacts

Wenbin Wei, PhD
study chair · Beijing Tongren Hospital
Xiuli Zhao, PhD
study chair · Beijing Tongren Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion